Post-Marketing Study Of Emergency Contraceptive Ella Would Be Challenging

FDA and its Reproductive Health Drugs Advisory Committee could not agree on the shape that post-marketing surveillance of HRA Pharma's emergency contraceptive Ella (ulipristal acetate) should take

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet